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A b s t r a c t  
Magnetoferritin, a synthetic derivate of iron storage protein – ferritin, has been synthesized with 
different iron oxide loading values. Small-angle neutron scattering experiments were applied to 
study the structure of magnetoferritin solutions using contrast variation method by varying the 
light to heavy water ratio of the solvent. Higher iron loading leads to increasing of the neutron 
scattering length density of magnetoferritin and also to the increase of the polydispersity of 
complexes. The formation of the magnetic core and the variation of the protein shell structure 
upon iron loading are concluded. 
 
1. Introduction  
In 1992 Meldrum and co-workers prepared new magnetic material called magnetoferritin. 
Magnetoferritin differs from the natural iron storage protein, ferritin, in the iron core 
composition of magnetic iron oxide phase (Fe3O4, γ−Fe2O3) surrounded by the protein shell – 
apoferritin with an outer diameter of about 12 nm [1]. Physico-chemical properties of 
magnetoferritin have been intensively studied. Bulte et al. studied magnetic properties of 
magnetoferritin and revealed superparamagnetic behavior of magnetoferritin dispersions [2]. 
Later, higher ratio of maghemite inside magnetoferritin was detected using Mössbauer 
spectroscopy in magnetic field at 9 T and at temperature 4.2 K [3,4]. The study of Wong et al. 
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confirmed the presence of superparamagnetic nanoparticles of Fe3O4 and γ-Fe2O3 in 
magnetoferritin, which was prepared by a chemical process using a controlled amount of 
oxidant, trimethylamine N-oxide, in anaerobic conditions, at temperature 65°C and pH 8.6. The 
new chemical method allowed to obtain magnetoferritin with various iron atoms per one 
apoferritin biomacromolecule (denoted as loading factor, LF). By transmission electron 
microscopy the aggregation of magnetoferritin with LF > 1000 was observed. Results have 
shown that with higher LF the diameter of nanoparticles increases [5,6]. The effect of dipolar 
interaction on temperature relaxation of magnetoferritin was studied and results were in a good 
agreement with theoretical models [7]. Kasyutich et al. in 2008 prepared three-dimensional 
arranged crystals of magnetoferritin with size about 10 to 100 micrometers by protein 
crystallization technology. [8,9]. Detailed investigation of magnetoferritin nanoparticles in 
solution using transmission electron microscopy, X-ray diffraction, atomic force microscopy by 
Martínez-Pérez et al. have shown that the external diameter of magnetoferritin nanoparticles 
increased with LF. The reason of this effect was related to conformational changes of the protein 
due to binding of iron oxides [10]. Recent studies of magnetically induced optical birefringence 
for colloidal dispersion of magnetoferritin in comparison with ferritin have shown differences in 
their magneto-optical behavior [11,12]. Magneto-optical Faraday rotation at room temperature in 
applied magnetic field with intensity H = 2970 Oe (i.e. 236.4 kA.m
-1
) showed different spectral 
dependences of the Faraday rotation on the wavelength allowing to distinguish ferritin and 
magnetoferritin. Dependence of the Faraday rotation of magnetoferritin as a function of applied 
magnetic field was characteristic for superparamagnetic system and could be modeled by the 
Langevin function with a log-normal size distribution of the magnetic particles [13]. 
Magnetoferritin was found to decompose hydrogen peroxide in the presence of the substrate, 
N,N-diethyl-p-phenylenediamine sulfate, which changed the color after the reaction. The 
peroxidase-like activity of magnetoferritin was more pronounced in the case of higher LF [14]. 
Physico-chemical characterization of magnetoferritin biomacromolecules in terms of 
morphology, structural and magnetic properties shows that iron oxides loaded into apoferritin 
affects the structure of protein shell [15,16]. However, the specific effect of magnetic 
nanoparticles and the role of the different amount of iron inside one biomacromolecule on the 
protein structure have not been fully determined yet.  
Extensive studies of magnetoferritin from the first synthesis in 1992 showed that its 
biological origin, well-defined diameter of nanoparticles, colloidal stability and 
superparamagnetic behavior provide significant potential of magnetoferritin for application in 
nanotechnology, industry, but especially in the biomedical sciences and cell biology [1,17]. The 
ability of magnetoferritin to undergo structure change under certain conditions enhances their 
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potential for various applications. Magnetoferritin structure can be modified by other substances 
[18], drugs, surfactants, signal molecules, antibodies [19,20],  resulting in change of the protein 
shell, so that the molecule can be completely closed, or partially open, or completely disrupted. 
Various potential applications are reported through chemical modifications of the external or 
internal surface, such as in magnetic resonance imaging of tissues [2,21], as contrast agent for 
cell labeling [22], as standard for diagnosis of various diseases [11-13], in nanocatalytical 
chemistry [14], cell separation [20] or in targeted transport of drugs. The drug binding to 
magnetoferritin allows visualization of pathological tissues or targeted transport directly only to 
the damaged area of the organism without the side effects of the drug on healthy tissues and 
organs [23]. All these applications rely on the ability of magnetoferritin to pertain or to change 
its core-shell structure.  
Small-angle neutron scattering (SANS) is an experimental method particularly suited to 
study the details of such core shell type objects of sizes 10-20 nanometers. Contrast variation 
technique in SANS can be used to reveal fine details of dispersions of multicomponent particles 
and clusters in liquid media. The structure and interactions of magnetic or non-magnetic particles 
can be obtained by the polarized neutron scattering analysis. A versatile approach to study 
polydisperse and nonhomogeneous particle dispersions by using contrast variation has been 
recently introduced [24,25]. Modifications of classical expressions describing changes in integral 
parameters of scattering (forward scattering intensity, radius of gyration, Porod integral) with the 
contrast are analyzed and the shape and size polydispersity is calculated. [24,25].  
In the present work, we investigated the structural changes of magnetoferritin with various 
loading factors by SANS contrast variation method. Results have shown the increase of effective 
match points and polydispersity of magnetoferritin with the LF growth. The magnetic core in 
magnetoferritin shifted the effective match points in comparison with pure apoferritin. Non-zero 
value of the forward scattering intensity in the effective match points indicated structural 
polydispersity, i.e. the non-uniform distribution of the iron oxide inside the protein cage. 
 
2. Materials and methods  
2.1 Chemicals 
Ammonium ferrous sulfate hexahydrate ((NH4)2Fe(SO4)2.6H2O), equine spleen 
apoferritin in 0.15 M NaCl, 3-[(1,1-dimethyl-2-hydroxy-ethyl)amino]-2-hydroxylpropane-
sulfonic acid (AMPSO), hydrogen peroxide (H2O2), hydrochlorid acid (HCl), potassium 
thiocyanate (KSCN), sodium hydroxide (NaOH) and trimethylamine N-oxide (Me3NO) were 
obtained from Sigma-Aldrich. 
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2.2  Magnetoferritin preparation 
Magnetoferritin was synthesized by incorporation of ferrous ions into the apoferritin 
hollow cage in 0.05 M AMPSO, pH 8.6 and anaerobic conditions at 65°C. Magnetoferritin 
complexes with four loading factors of 160, 510, 766 and 910, were prepared. The LF was 
determined spectrophotometrically using UV-VIS spectrophotometer SPECORD 40, Analytik 
Jena, with precision about 1%. Concentration of iron was measured after HCl/H2O2 oxidation and 
KSCN addition by light absorption of thiocyanate complex at wavelength (λ) 400 nm. Protein 
amount was detected using standard Bradford method at λ = 595 nm. After the synthesis samples 
were 24 h freeze dried to obtain a powder. Finally, 10 mg/ml solutions of protein were prepared 
by dissolving powders in AMPSO alkaline buffer solution with various ratio of H2O:D2O for 
contrast variation method. AMPSO alkaline buffer solutions of similar H2O:D2O ratios were 
used for incoherent background measurements.  
 
2.3 Small-angle neutron scattering experiment 
SANS measurements were carried out on small-angle neutron scattering spectrometer 
YuMO [26,27] installed on the pulsed nuclear reactor IBR-2 at the Joint Institute for Nuclear 
Research (JINR, Russia). Samples were located in standard quartz cuvettes (Hellma) with a 
thickness of 1 mm and the measurements were performed at room temperature in the absence of 
external magnetic field.  Thermal non-polarized neutrons of wavelengths between 0.5 Å and 8 Å 
were used.  The measured scattering curves were corrected for the scattering from the solvent 
and the absolute cross section was determined by vanadium calibration standards.  
 
3. Results and discussions 
The small-angle neutron scattering from magnetoferritin aqueous suspensions was 
measured at the different D2O content in the solvent. Experimental scattering curves for 
apoferritin (concentration about 12 mg/ml) and magnetoferritin with LF 160, 510, 770, and 910 
in 100% D2O, after subtraction of scattering from AMPSO buffer, are shown in Fig. 1.  
Smoothing of the measured SANS curve in comparison with pure apoferritin is seen like in 
previous works [15,16]. Similar behavior of SANS curves at varying H2O/D2O content is 
obtained for all studied LFs except for LF 910. For magnetoferritin with LF 910 dark precipitates 
sedimented to the bottom of the cell. Therefore, only MFer 910 in 100% D2O was measured. As 
an example, SANS curves of magnetoferritin with LF 770 in various ratios of H2O and D2O with 
protein concentration of 10 mg/ml are shown in Fig 2a.). From linear fitting of Guinier plots 
(Fig. 2b.)) values of the forward scattering intensity, I(0), and radius of the gyration, Rg were 
obtained. The scattering length densities (SLDs) of the solvent mixtures, ρs, were calculated 
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using the SLD of H2O and D2O values (ρH2O = -0.559. 10
10
 cm
-2
, ρD2O = 6.34. 10
10
 cm
-2
). The 
lowest value of I(0) corresponds to the match point. For homogeneous particles, the scattering 
length density of the solvent and particles coincides in the match point. Non-zero value of the 
forward scattering intensity in the match point, as shown in Fig. 3, indicates structural 
polydispersity in the system. The match point is shifted with increasing loading factor (Fig. 3). In 
this analysis, the magnetic scattering intensity contribution can be neglected.  The contribution of 
magnetic scattering for LF 770 is less than 5%, assuming magnetite in the protein cage. 
Magnetometry data on similar samples indicated magnetization values below 0.05 A m
2
 kg
-1 
[6,14], which is much lower than the specific magnetization of apoferritin filled with magnetite 
phase. Already in the monodisperse approximation and assuming that the magnetic core in 
magnetoferritin consists of magnetite, the shifts of the effective match points  as compared to the 
protein moiety of apoferritin (SLD 2.34. 10
10
 cm
-2
) give 0.026, 0.099 and 0.114 respectively, for 
the volume fractions of magnetic material in the magnetoferritin cage (corresponding SLDs are 
2.46. 10
10
 cm
-2
, 2.79. 10
10
 cm
-2
, and 2.86. 10
10
 cm
-2
 for LF 160,  LF 510 and LF 770, 
respectively). These apparent volume fractions obtained from the measurements are about 3-5 
times larger than what could be caused by the iron oxide loading in the synthesis (0.005, 0.017 
and 0.025 for LF 160, LF 510 and LF 770, respectively). The calculated match points are 
significantly higher than those for native ferritin with different amount of iron [28]; they 
correspond to native ferritin with about 800 and 2000 iron atoms per protein shell. Thus, SANS 
contrast variation measurements indicated an abnormally high ratio of the amount of the iron 
oxide phase to the protein. The reason of this increase can be explained by the partial destruction 
of the shell, and thus the effective growth of the relative content of the magnetic component in 
the magnetoferritin. The residual scattering in the effective match points increases in accordance 
with the broadening of the polydispersity function for larger LFs, in agreement with the 
increased polydispersity observed in magnetooptical measurements [11,12] 
The precise mechanism of magnetic loading influence on the protein structure is not known 
yet. In a recent study apoferritin disassembly was observed at pH below 3.4 [29].  This is 
however not our case, since our magnetoferritin was prepared in alkaline pH (pH 8.6 for each 
synthesis). While it was not possible to control pH directly during the synthesis process due to 
the hermetically enclosed reaction bottle, still after the synthesis the pH value was checked and 
only slight pH change, namely some decrease for higher LFs, was detected but the minimum pH 
after the synthesis was above 7 for all LFs. 
The observed disassembly of magnetoferritin cage can be related to the influence of the 
magnetic nanoparticles. Interaction between magnetic nanoparticles and proteins is the subject of 
6 
 
extensive studies in recent years and the general conclusion is that different nanoparticles with 
specific concentration, surface and size can affect proteins structural conformations [30-34]. 
 
4. Conclusions 
We studied the structural changes of magnetoferritin in aqueous solution with LFs: 160, 
510, 770 and 910 by contrast variation small angle neutron scattering.  The obtained values of 
the average neutron scattering length density of magnetoferritin (effective match point) and its 
variation among the aggregates increased with iron loading. This effect can be associated with 
formation of magnetic iron oxide nanoparticles inside complexes and their influence on the 
protein structure. While the scattering data could give only an average information on the 
structural properties of the complexes, other experimental techniques, such as electron 
microscopy or fluorescence spectroscopy could serve with more direct information on the 
structure and conformational changes of magnetoferritin upon variation of the iron loading.   
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Fig. 1 Experimental scattering curves of magnetoferritins (LF 160, 510, 770, 910) and apoferritin 
in 100% D2O with protein concentration of about 12 mg/ml for apoferritin and 10 mg/ml for 
magnetoferritin samples. 
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Fig. 2 Scattering curves of magnetoferritin LF 770 in various ratios of H2O and D2O with protein 
concentration of 10 mg/ml (a) and the corresponding Guinier plots (b). 
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Fig. 3 Scattering intensity at the zero angle as a function of the D2O content (. The minima of 
the fitted parabolas show the effective match points at the studied loading factors.  
